IDEA: Pooled Analysis of Adjuvant Oxaliplatin for 3 vs 6 Mos in Stage III Colon Cancer

June 2-6, 2017; Chicago, Illinois
In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.
Format: Microsoft PowerPoint (.ppt)
File Size: 232 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

DESTINY-Gastric02 trial: T-DXd demonstrated activity as second-line treatment in Western patients with HER2+ advanced gastric/GEJ cancer; from ESMO 2021 and Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 22, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Enter the characteristics of your patients with pancreatic cancer into this online tool from Clinical Care Options (CCO) to receive expert treatment recommendations

Andrew H. Ko, MD
Program Director
Elena Gabriela Chiorean, MD Dan Laheru, MD person default Paul E. Oberstein, MD Michael J. Pishvaian, MD, PhD
Released: September 13, 2021

From Clinical Care Options (CCO), download a PDF featuring expert discussion of biomarkers in gastrointestinal cancers

John L. Marshall, MD Released: August 18, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue